The FDA Law Blog

JANUARY 18, 2024

Houck — In August 2023 the Food and Drug Administration (“FDA”) and Health and Human Services (“HHS”) recommended that the Drug Enforcement Administration (“DEA”) reschedule marijuana from schedule I under the federal Controlled Substances Act (“CSA”) to schedule III. chemotherapy-induced), pain, and post-traumatic stress disorder.

FDA 69

FDA Controlled Substances Chemotherapy Compounding 69

The Checkup by Singlecare

MARCH 23, 2023

Understanding the difference between CBD vs. marijuana Cannabinoids are compounds found in the cannabis plant, Cannabis sativa. The United States Congress legalized CBD derived from hemp in 2018 when the Agricultural Improvement Act was signed into law, removing hemp from the Federal Controlled Substances Act.

Controlled Substances 52

Controlled Substances Medical Records Chemotherapy Compounding 52

The FDA Law Blog

FEBRUARY 11, 2024

Few would oppose FDA-approved marijuana-derived medications if marijuana compounds are found to have medical value; the National Institute of Health should continue to fund research on any potential medical value of marijuana and on the harms of highly potent products.

Controlled Substances 59

Controlled Substances Chemotherapy FDA Compounding 59